Clinical Trials with Mesenchymal Stem Cells: An Update
Top Cited Papers
Open Access
- 1 May 2016
- journal article
- review article
- Published by SAGE Publications in Cell Transplantation
- Vol. 25 (5), 829-848
- https://doi.org/10.3727/096368915x689622
Abstract
In the last year, the promising features of mesenchymal stem cells (MSCs), including their regenerative properties and ability to differentiate into diverse cell lineages, have generated great interest among researchers whose work has offered intriguing perspectives on cell-based therapies for various diseases. Currently the most commonly used adult stem cells in regenerative medicine, MSCs, can be isolated from several tissues, exhibit a strong capacity for replication in vitro, and can differentiate into osteoblasts, chondrocytes, and adipocytes. However, heterogeneous procedures for isolating and cultivating MSCs among laboratories have prompted the International Society for Cellular Therapy (ISCT) to issue criteria for identifying unique populations of these cells. Consequently, the isolation of MSCs according to ISCT criteria has produced heterogeneous, nonclonal cultures of stromal cells containing stem cells with different multipotent properties, committed progenitors, and differentiated cells. Though the nature and functions of MSCs remain unclear, nonclonal stromal cultures obtained from bone marrow and other tissues currently serve as sources of putative MSCs for therapeutic purposes, and several findings underscore their effectiveness in treating different diseases. To date, 493 MSC-based clinical trials, either complete or ongoing, appear in the database of the US National Institutes of Health. In the present article, we provide a comprehensive review of MSC-based clinical trials conducted worldwide that scrutinizes biological properties of MSCs, elucidates recent clinical findings and clinical trial phases of investigation, highlights therapeutic effects of MSCs, and identifies principal criticisms of the use of these cells. In particular, we analyze clinical trials using MSCs for representative diseases, including hematological disease, graft-versus-host disease, organ transplantation, diabetes, inflammatory diseases, and diseases in the liver, kidney, and lung, as well as cardiovascular, bone and cartilage, neurological, and autoimmune diseases.Keywords
This publication has 129 references indexed in Scilit:
- Clinical applications of mesenchymal stem cellsJournal of Hematology & Oncology, 2012
- The role of immunosuppression of mesenchymal stem cells in tissue repair and tumor growthCell & Bioscience, 2012
- Mesenchymal Stem Cells Induce Functionally Active T-Regulatory Lymphocytes in a Paracrine Fashion and Ameliorate Experimental Autoimmune UveitisInvestigative Opthalmology & Visual Science, 2012
- The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsTrials, 2011
- Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosisJournal of Translational Medicine, 2009
- Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and HumansThe International Journal of Cell Cloning, 2009
- Developments in the clinical understanding of lupusArthritis Research & Therapy, 2009
- Collection, Cryopreservation, and Characterization of Human Dental Pulp–Derived Mesenchymal Stem Cells for Banking and Clinical UseTissue Engineering, Part C: Methods, 2008
- Human cardiac stem cellsProceedings of the National Academy of Sciences, 2007
- How I treat refractory acute GVHDBlood, 2007